Montana Targets Lilly in Zyprexa Lawsuit
- March 28, 2007
Montana is the seventh state to sue the pharmaceutical giant Eli Lilly over the company's blockbuster antipsychotic Zyprexa. The lawsuit cites fraudulent marketing practices and is seeking reimbursement for Medicaid prescriptions and patient harm.
Lilly has recently settled more than 28,000 Zyprexa lawsuits for a reported 1.2 billion over claims that the drug caused serious side effects such as high blood sugar and diabetes.
However, the company is still facing as many as 1,300 additional claims as well as lawsuits filed by Pennsylvania, West Virginia, New Mexico, Alaska, Louisiana, and Mississippi.
The complaint filed in Montana claims that Lilly “instructed its representatives to minimize and misrepresent the dangers of Zyprexa, affirmatively and consciously placing company profits above the public safety.”
Zyprexa is FDA approved for the treatment of schizophrenia and bipolar disorder, but the company is accused of promoting the drug for a variety of off-label purposes including depression, autism, and dementia.
Federal law allows doctors to prescribe drugs for uses that aren't FDA approved, but does not allow pharmaceutical companies to market their drugs for these purposes.
According to Montana's lawsuit, Lilly employed a 280-person sales force “to promote Zyprexa exclusively for off-label uses, specifically for long-term-care facilities to maximize off-label use of Zyprexa sales.”
The company is currently facing a federal probe into its marketing practices. In the meantime, Montana is seeking unspecified damages related to prescription costs and harm done to patients.
Injured by Zyprexa? It's not to late to seek reimbursement for your losses and suffering. Please contact us today for a FREE case evaluation with an experienced Zyprexa lawyer.